We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 225

Intellectual property weekly abstracts bulletin Week of July 14

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • July 17 2014

Allianz Asset Management of America L.P. (“AAMA”) and Allianz Global Investors of America L.P. (“AGIA”) appealed two decisions of the Trade-marks

Intellectual property weekly abstracts bulletin

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • April 1 2013

The Court granted a Prohibition Order to AstraZeneca, preventing Ranbaxy from entering the market with a generic version of ompeprazole until the

Leave to amend Statement of Defence denied

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • April 18 2011

Shire brought a motion seeking leave to amend its Statement of Defence to add a new defence of infringement as well as a defence of failure to mitigate

BBM Canada v. Research in Motion Limited

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • May 16 2011

This was an appeal from a decision that found a claim relating to trade-mark infringement, depreciation of goodwill and passing off may not be brought as an application in the Federal Court

Antibody patent found valid and infringed

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • January 27 2014

The Court recently decided a patent infringement case dealing with antibodies. The claims at issue in AbbVie’s patent relate to the use of a human

Court grants motion to reopen trial and admit new evidence

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • April 27 2011

The Federal Court granted leave to reopen the trial and admit new evidence in a matter under reserve, in which no reasons or judgement have issued

NOC proceeding dismissed on the basis of overbreadth and a lack of sound prediction

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • February 13 2013

In this case, one claim of a patent was at issue in the proceeding. The claim related to the use of pregabalin or its racemate to treat pain. The

Other IP industry news of note

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • August 11 2010

The Natural Health Products Directorate (NHPD) sent an email to those signed up to its Electronic Subscriber Service indicating that the Natural Health Products (Unprocessed Product License Applications) Regulations were adopted and came into force on August 4, 2010 and will be published in the Canada Gazette, Part II in the upcoming weeks

Leave denied by Supreme Court of Canada with respect to data protection legislation

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • July 18 2011

The Supreme Court of Canada denied leave from a decision of the Federal Court of Appeal finding that the data protection provisions of the Food and Drugs Regulations are intra vires

Bayer v. Minister of Health

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • June 28 2010

The Court of Appeal upheld the decision of the Federal Court, dismissing the application by Bayer for a review of the decision of the Minister of Health refusing to list a patent on the Patent Register in respect of its drug product